The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2019 | Radical treatment for oligometastatic NSCLC
Fiona McDonald, MA, MBBS, MRCP, FRCR, MD, of the Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK, discusses oligometastatic non-small cell lung cancer (NSCLC), and whether radical treatment should be the standard of care for this disease. Dr McDonald highlights a recent update on a study (NCT01725165) that revealed exciting overall survival data in the synchronous oligometastatic setting, as well as the first randomized evidence to also suggest a survival benefit in the metachronous oligometastatic setting. Looking towards the future, she discusses the UK-based Stereotactic Ablative Radiotherapy for Oligometastatic NSCLC (SARON; NCT02417662) and Conventional Care Versus Radioablation for Extracranial Oligometastases (CORE; NCT02759783) studies. Lastly, oligoprogressive disease is discussed; including the HALT study (ISRCTN53398136). This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference in Dublin, Ireland.
